Despite the high frequency of RAS mutations, the majority of MM tumors harboring RAS mutations have no detectable MEK activity by immunohistochemistry staining7 or analysis of MAPK-dependent transcription8, and MEK inhibitors have only had modest success treating MM patients in the clinic9,10. This evidence concerns the gene MAP2K7 and Miyoshi myopathy.